share_log

MediciNova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of MN-166 In ALS At The 35th International Symposium On ALS/MND

Benzinga ·  Dec 5, 2024 18:04

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company's COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada.

The highlights of the presentation, titled, "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results" (Abstract # 302), include:

  • Study Update: As of November 15, 2024, a total of 217 participants have been enrolled...
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment